BrexafemmeActive Ingredient(s): Ibrexafungerp Citrate
FDA Approved: * June 1, 2021
Pharm Company: * SCYNEXIS
Ibrexafungerp, sold under the brand name Brexafemme, is an antifungal medication used to treat vulvovaginal candidiasis (VVC) (vaginal yeast infection). It is taken by mouth. Ibrexafungerp is a triterpenoid antifungal. Ibrexafungerp was approved for medical use in the United States in June 2021. It is the first approved drug in a novel antifungal class. Contents 1 Medical uses 2... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.